April 2015: OCTO News


Recruitment to the first two dose levels has completed with the combination of BKM120 and radiotherapy being well tolerated. The study is now recruiting patients to the third and final dose level.


The final datalock for 6MP Trial is scheduled for beginning of June. The clinical paper will be written with the aim to send to the chosen Journal in September 2015.


SPARC trial is now open to recruitment at The Churchill Hospital, Oxford University Hospitals NHS Trust. This is a phase 1 study dose escalation study testing the use of Stereotactic Body Radiation Therapy (SBRT) delivered in the pre-operative setting for borderline resectable pancreatic cancers.

The primary objective is to determine the maximum tolerated dose (MTD) of margin-intensive SBRT delivered pre-operatively in the surgical management of pancreatic cancer.

Site set-up is progressing well at our other two study sites (Leeds Cancer Centre and The Beatson West of Scotland Cancer Centre, Glasgow). If you have any questions about the trial please contact the SPARC Trial team.


LINES & MEMOS opened to recruitment in the first non-UK centre in January 2015 & February 2015 respectively, at Istituti Ortopedici Rizzoli, Bologna, Italy
Principal Investigator: Dr Stefano Ferrari


An extension to the recruitment period has been granted, with recruitment now open until January 2016.

The expansion of the trial into Germany continues to go well, with 7 sites now activate and 7 patients recruited to date (22Apr2015).

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.